Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 1218-1225

  Bloomfield, D J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID;

ANALGESIA; BONE CANCER; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PAIN; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; EVIDENCE BASED MEDICINE; EYE TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0031909288     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.1218     Document Type: Review

References (42)

1. Abrams HL, Spiro R, Goldstein N: Metastases in carcinomas: Analysis of 1000 autopsied cases. Cancer 23:74-85, 1950
2. Urwin GH, Percival RC, Harris S, et al: Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 57:721-723, 1985
3. Cancer Statistics 1997. CA Cancer J Clinicians vol 47, 1997
4. Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66, 1987
5. Coleman RE, Purohit OP: Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 19:79-103, 1993
6. A report by the Canadian Task Force on the Periodic Health Examination: Assessing the clinical effectiveness of preventive maneuvers: Analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. J Clin Epidemiol 43:891-905, 1990
7. Browman GP, Levine MN, Mohide EA, et al: The Practice Guidelines development cycle: A conceptual tool for practice guidelines development and implementation: J Clin Oncol 13:502-512, 1995
8. Laupacis A, Sackett DL, Roberts RS: An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318:1728-1733, 1988
9. Dickersin K, Hewitt P, Mutch L et al: Perusing the literature: Comparison of MEDLINE searching with a perinatal trials base. Control Clin Trials 6:306-317, 1985
10. Sackett DL: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 89:25-35, 1986 (suppl)
11. Royall RM: The effect of sample size on the meaning of significance tests. Am Stat 40:313-315, 1986
12. Belch AR, Bergsagel DE, Wilson K, et al: Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9:1397-1402, 1991
13. Fleisch H: Bisphosphonates: Pharmacology and use in the treatment of tumour induced hypercalcaemic and metastatic bone disease. Drugs 42:919-944, 1991
14. Lahtinen R, Laakso M, Palva I, et al: Randomised placebo controlled multicentre trial of clodronate in multiple myeloma. Lancet 340:1049-1052, 1992
15. Berenson JR, Lichtenstein A, Porter L, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488-493, 1996
16. McCloskey EV, Maclennan I, Grayson M, et al: Oral clodronate reduces skeletal morbidity in multiple myelomatosis. Bone Miner 25:S80, 1994 (suppl)
17. Elomaa I, Blomqvist C, Grohn P: Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1:146-149, 1983
18. Elomaa I, Blomqvist C, Porkka L: Treatment of skeletal disease in breast cancer: A controlled clodronate trial. Bone 8:S53-S56, 1987 (suppl 1)
19. Elomaa I, Blomqvist C, Porkka L: Clodronate for osteolytic metastases due to breast cancer. Biomed Pharmacother 42:111-116, 1988
20. Sins E, Hyman G, Canfield R: Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 74:401-406, 1983
21. Van Holten-Verzantvoort A, Bijvoet O, Cleton F, et al: Reduced morbidity from skeletal metastases in breast cancer patients during long term biphosphonate (APD) treatment. Lancet 2:983-985, 1987
22. Van Holten-Verzantvoort A, Zwinderman A, Aaronson N, et al: The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 27:544-549, 1991
23. Van Holten-Verzantvoort A, Kroon H, Bijvoet F: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491-498, 1993
24. Van Holten-Verzantvoort A, Hermans J, Beex L: Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur J Cancer 32A:450-454, 1996
25. Conte PF, Gianessi PG, Latreille J, et al: Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: A Randomised, multicenter phase III trial. Ann Oncol 5:S41-S44, 1994 (suppl 7)
26. Conte PF, Latreille L, Mauriac L, et al: Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial. J Clin Oncol 14:2552-2559, 1996
27. Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and bone metastases. N Engl J Med 335:1785-1791, 1996
28. Paterson A, Powles T, Kanis J, et al: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65, 1993
29. Kanis JA, Powles TJ, Paterson AHG, et al: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19:663-667, 1996
30. Theriault R, Lipton A, Hershey PA, et al: Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly pamidronate sodium infusion. Proc Am Soc Clin Oncol 15:122, 1996 (abstr 152)
31. Elomaa I, Kylmala T, Tammela T, et al: Effect of oral clodronate on bone pain - A controlled study in patients with metastatic prostatic cancer: Int Urol Nephrol 24:159-166, 1992
32. Kymala T, Tammela T, Risteli L, et al: Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 29a:821-825, 1993
33. Smith JA: Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of a randomized, prospective, double blind, placebo-controlled study. J Urol 141:85-87, 1989
34. Ernst SD, MacDonald N, Paterson A, et al: A double blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 7:4-11, 1992
35. Robertson AG, Reed NS, Ralston SH: Effect of oral clodronate on metastatic bone pain: A double blind, placebo controlled study. J Clin Oncol 13:2427-2430, 1995
36. Coleman RE, Vinholes J, Abbey ME, et al: Double blind randomised trial of pamidronate (aredia) for the palliative treatment of metastatic bone disease. Proc Am Soc Clin Oncol 15:528, 1996 (abstr 1706)
37. Ghose K, Waterworth R, Trolove P, et al: Uveitis associated with pamidronate. Aust NZ J Med 24:320, 1994
38. Macarol V, Fraunfelder FT: Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118:220-224, 1994
39. O'Donnell NP, Rao GP, Aguis-Fernandez A: Pagets disease: Ocular complications of disodium pamidronate treatment. Br J Clin Pract 49:272-273, 1995
40. Purohit OP, Radstone CR, Anthony C, et al: A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 72:1289-1293, 1995
41. Ralston SH, Gallacher SJ, Patel U, et al: Comparison of three intravenous bisphosphonates in cancer associated hypercalcaemia. Lancet 2:1180-1182, 1989
42. Eddy DM: Clinical policies and the quality of clinical practice. N Engl J Med 307:343-347, 1982